N/A
N=32
Randomized Clinical Trial on Transanal Irrigation
Low Anterior Resection Syndrome
Bottom Line
View on ClinicalTrials.gov: NCT04586634 ↗Enrolled (actual)
32
Serious AEs
0.0%
Results posted
Jul 2024
Primary outcome: Primary: LARS Score — 21.3; 32.2 score on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Peristeen cone catheter (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Coloplast A/S
- Primary completion
- Dec 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY LARS Score |
21.3; 32.2 | — |
| SECONDARY Number of Subjects With Major LARS |
5; 10 | — |
| SECONDARY FIQL Score - Scale 1 Lifestyle, Modified American Society for Colorectal Surgeons Questionnaire |
3.10; 2.60 | — |
| SECONDARY FIQL Score - Scale 2 Coping/Behavior, Modified American Society for Colorectal Surgeons Questionnaire |
2.95; 2.37 | — |
| SECONDARY FIQL Score - Scale 3 Depression/Self-perception, Modified American Society for Colorectal Surgeons Questionnaire |
3.41; 3.23 | — |
| SECONDARY FIQL Score - Scale 4 Embarrassment , Modified American Society For Colorectal Surgeons Questionnaire |
2.98; 2.76 | — |
| SECONDARY EQ-5D-5L - Utility Score |
0.92; 0.88 | — |
| SECONDARY EQ-5D-5L - VAS Score |
82.8; 71.4 | — |
| SECONDARY Satisfaction With Treatment |
8.6; 5.9 | — |
Summary
Objective The primary objective is to demonstrate superiority of the Peristeen cone catheter compared to standard of care.
The secondary objective is to investigate quality of life and different benefits and aspects of treatment and satisfaction with the Peristeen cone catheter.
Design of the investigation This is a randomised, open-label, parallel investigation comparing the Peristeen cone catheter with standard of care in subjects with major LARS (LARS score ≥ 30). Each subject will be enrolled for a study duration of 12 weeks. Subjects will be randomized to the treatments stratified by neo-adjuvant radiotherapy.
The comparator in this study will be current standard of care for patients with LARS which is conservative bowel management. This is defined as: Supportive therapy according to the individual treatment protocols available at each participating site.
Primary endpoint and secondary endpoints
Primary endpoint:
• LARS score, obtained from the LARS score questionnaire*
Secondary endpoints:
* Number of subjects with Major LARS*
* FIQL Score - scale 1, Modified American Society for Colorectal Surgeons Questionnaire*
* FIQL Score - scale 2, Modified American Society for Colorectal Surgeons Questionnaire*
* FIQL Score - scale 3, Modified American Society for Colorectal Surgeons Questionnaire*
* FIQL Score - scale 4, Modified American Society for Colorectal Surgeons Questionnaire*
* EQ-5D-5L - utility score*
* EQ-5D-5L - VAS score (scale 0-10 cm)*
* Satisfaction with treatment (scale 0-10 cm)*
* Number of adverse events* *All endpoints are measured per subject at study completion
Eligibility Criteria
Inclusion Criteria
- Be at least 18 years of age and have full legal Capacity
- Have given written informed consent
- Be mental and physical capable to perform transanal irrigation with cone catheter
- Have a LARS score ≥ 30 after rectal resection
- Be treated according to individual treatment protocol for conservatory bowel management at participating site
- Have proof of complete healing of the anastomosis by endoscopy or radiology before stoma closure
- At least 3-months from last surgery in colorectum
- Be evaluated to be suitable for transanal Irrigation procedure with a cone catheter by endoscopy, defecography or comparable procedure
Exclusion Criteria
- Active/recurrent colorectal cancer
- Leaking anastomosis
- Known anal or colorectal stenosis
- Within 4 weeks of endoscopic polypectomy
- Ischaemic colitis
- Acute inflammatory bowel disease
- Acute diverticulitis
- Current or planned pregnancy
Data sourced from ClinicalTrials.gov (NCT04586634). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.